At a pivotal juncture for the Greek healthcare system, the PhARMA Innovation Forum (PIF) Greece has announced its new leadership, with Kavita Patel, General Manager of Roche Hellas, taking the reins as President. The election of the new Board of Directors for the 2024-2027 term is not merely an internal administrative change; it signals the beginning of a period of intense advocacy for the modernization of pharmaceutical policy in Greece. Representing 26 of the world's leading biotechnology and research companies, PIF is tasked with bridging the gap between rapid scientific progress and the fiscal constraints that characterize the Greek market.
The New Leadership Strategy and Priorities
Kavita Patel assumes her duties at a time when healthcare innovation is undergoing a radical transformation. From personalized medicine and immuno-oncology to gene therapies, science is offering solutions that seemed unthinkable just a few years ago. However, integrating these solutions into the national health system requires more than scientific excellence: it requires a predictable and sustainable funding framework. The new President has set the acceleration of patient access to these treatments as a core pillar of her mandate, noting that delays in the approval and reimbursement of new drugs in Greece remain significantly higher than the European average.
The new Board, supported by seasoned industry executives from companies like Pfizer, Sanofi, Novartis, and AstraZeneca, aims to highlight the value of innovation as an investment rather than an expense. PIF's strategy for the next three years focuses on revising incentives for Research and Development (R&D) and ensuring that Greek patients are not "second-class citizens" regarding the availability of the most modern therapeutic options.
The Clawback Thorn and the Quest for Sustainability
No discussion on pharmaceutical innovation in Greece can occur without addressing the issue of automatic returns (clawback) and mandatory discounts (rebates). This system, established as an emergency measure during the economic crisis, has evolved into a permanent mechanism that threatens the viability of companies. PIF has repeatedly emphasized that excessive burdens, which often exceed 40% or even 50% of turnover for certain innovative treatments, act as a deterrent to introducing new medicines to the country.
Ms. Patel's leadership is expected to intensify the dialogue with the Ministry of Health and the Ministry of Finance to rationalize pharmaceutical spending. The challenge is twofold: on one hand, the state must control its expenditures, and on the other, companies need a stable environment to continue investing. PIF proposes the use of digital tools and Real-World Evidence (RWE) to better target treatments and reduce waste, rather than horizontal spending cuts that indiscriminately hit innovation.
Greece as a Clinical Research Hub
One of the most ambitious goals of the new Board is to establish Greece as a regional hub for clinical trials. The country possesses exceptional scientific talent and hospital infrastructure that, if properly utilized, could attract hundreds of millions of euros in foreign investment annually. Clinical trials offer multiple benefits: free access to groundbreaking treatments for patients, capital inflow into the healthcare system, and a reversal of the "brain drain" for Greek researchers.
However, bureaucracy and approval delays remain a significant bottleneck. PIF, under its new leadership, intends to work closely with relevant authorities to simplify procedures. Success in this area could change the narrative for the pharmaceutical industry in Greece, transforming it from a sector that "costs" the state into one that generates wealth and high added value for the economy and society.
Digitalization and the Road Ahead
Finally, the digitalization of healthcare is an integral part of Kavita Patel's agenda. The full implementation of the electronic health record, the interconnection of hospitals, and the use of Artificial Intelligence in diagnosis and treatment are essential steps for a modern state. PIF argues that technology can provide the transparency currently lacking in the system, allowing decision-makers to know exactly where every euro goes and what the actual therapeutic benefit for the patient is. Looking towards 2027, the new leadership of the PhARMA Innovation Forum must prove that innovation is the only path toward a sustainable and fair healthcare system.
